AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
190.75
+0.76 (0.40%)
At close: Jul 2, 2025, 4:00 PM
190.74
-0.01 (-0.01%)
After-hours: Jul 2, 2025, 7:54 PM EDT
AbbVie Revenue
AbbVie had revenue of $13.34B in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
5.88
Revenue / Employee
$1,043,036
Employees
55,000
Market Cap
336.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 42.90B |
ABBV News
- 13 hours ago - AbbVie Stock At $190: Premium Pricing For A Transformation Story - Forbes
- 2 days ago - AbbVie to buy Capstan Therapeutics for up to $2.1 billion - Reuters
- 2 days ago - AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology - PRNewsWire
- 2 days ago - U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance - PRNewsWire
- 2 days ago - AbbVie to Host Second-Quarter 2025 Earnings Conference Call - PRNewsWire
- 2 days ago - This Changes Everything: One Of The Most Important Shifts For Dividend Investors - Seeking Alpha
- 3 days ago - Best Dividend Aristocrats For July 2025 - Seeking Alpha
- 7 days ago - Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer - GlobeNewsWire